The approaches taken by the authors seem sound and the findings are interesting and suggestive. Synthesis of a solely calpain-specific low molecular weight inhibitor may lead to a "dream medication" that can be used to treat Alzheimer's disease, vascular dementia, Parkinson's disease, polyglutamine disease, and now prion disease. There remains, however, a very basic question regarding this particular work: How can calpains, exclusively intracytoplasmic proteins, have access to PrP, a GPI-anchored extracytoplasmic protein?
Comments
RIKEN Center for Brain Science
The approaches taken by the authors seem sound and the findings are interesting and suggestive. Synthesis of a solely calpain-specific low molecular weight inhibitor may lead to a "dream medication" that can be used to treat Alzheimer's disease, vascular dementia, Parkinson's disease, polyglutamine disease, and now prion disease. There remains, however, a very basic question regarding this particular work: How can calpains, exclusively intracytoplasmic proteins, have access to PrP, a GPI-anchored extracytoplasmic protein?
Make a Comment
To make a comment you must login or register.